Premium
Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B
Author(s) -
Djulbegovic Benjamin,
Marasa Mary,
Pesto Al,
Kushner George M.,
Hadley Terence,
Joseph Geetha,
Goldsmith George
Publication year - 1996
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199602)51:2<168::aid-ajh14>3.0.co;2-e
Subject(s) - medicine , tranexamic acid , antifibrinolytic , hemostasis , factor ix , hematocrit , coagulation , surgery , aminocaproic acid , hemostatics , thrombosis , prothrombin complex concentrate , gastroenterology , anesthesia , warfarin , blood loss , atrial fibrillation
This study evaluated the safety and efficacy of combined treatment with ϵ‐aminocaproic acid or tranexamic acid and monoclonal antibody purified factor IX (MAb factor IX) for prophylaxis against bleeding in eight hemophilia B patients undergoing nine dental extraction procedures. All patients achieved excellent hemostasis without clinical evidence of thrombosis. There were no significant changes in hemoglobin or hematocrit or in markers of hemostatic system activation (prothrombin fragment F 1–2 , fibrinopeptide A, and fragment B β 15–42 ) after surgery. Thus, a highly purified factor IX concentrate and antifibrinolytic therapy can be effectively and safely combined in hemophilia B patients undergoing dental extractions. © 1996 Wiley‐Liss, Inc.